Triglycerides, High-Density Lipoprotein Cholesterol, and Risk of Ischemic Heart Disease: A View from the Copenhagen Male Study

Metabolic Syndrome and Related Disorders

Volumn 1, Issue 1, 2003, Pages 33-53

  Jeppesen, JØrgen ^a  

^a BISPEBJERG HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33750355641     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/154041903321648243     Document Type: Review

References (115)

1. Kannel WB, Dawber TR, Friedman GD, et al. Risk factors in coronary heart disease: An evaluation of several serum lipids as predictors of coronary heart disease. Ann Intern Med 1964; 61: 888–899.
2. Kannel WB, Castelli WP, Gordon T, et al. Serum cholesterol, lipoproteins and risk of coronary heart disease: The Framingham Study. Ann Intern Med 1971; 74: 1–12.
3. Rosenman RH, Brand RJ, Jenkins D, et al. Coronary heart disease in Western Collaborative Group Study: Final follow-up experience of 8½ years. JAMA 1975; 233: 872–877.
4. Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease: The Framingham Study. Am J Med 1977; 62: 707–714.
5. Miller NE, Forde OH, Thelle DS, et al. The Tromso Heart Study: High-density lipoprotein and coronary heart disease: a prospective case-control study. Lancet 1977; 1: 965–70
6. Brown DF, Kinch SH, Doyle JT. Serum triglycerides in health and in ischemic heart disease. N Engl J Med 1965; 273: 947–952.
7. Scandinavian Simvastatin Survival Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389.
8. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1310–1317.
9. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615–1622.
10. Grundy SM, Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation 1997; 95: 1–4.
11. Wilsen PWF, Anderson KM, Castelli WP, et al. Twelve-year incidence of coronary heart disease in middle-aged adult during the era of hypertensive therapy: The Framingham Offspring Study. Am J Med 1991; 90: 11–16.
12. Després JP, Lemieux I, Dagenais GR, et al. HDL-cholesterol as a marker of coronary heart disease risk: The Québec cardiovascular study. Atherosclerosis 2000; 153: 263–272.
13. Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein (a), apolipoproteins A-1 and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001; 104: 1108–1113.
14. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1991; 11: 2–14.
15. Parter PJ, Rye KA. High density lipoproteins and coronary heart disease. Atherosclerosis 1996; 121: 1–12.
16. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prosepctive american studies. Circulation 1989; 79: 8–15.
17. Von Eckardstein A, Nofer JR, Assmann G. High density lipoproteins and arteriosclerosis: role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2001; 21: 13–27.
18. Gotto AM. Low high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report. Circulation 2001; 103: 2213–2218.
19. Gotto AM. Triglyceride: the forgotten risk factor. Circulation 1998; 97: 1027–1028.
20. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3: 213–219.
21. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–1607.
22. Gyntelberg F. Physical fitness and coronary heart disease in male residents in Copenhagen aged 40–59. Danish Med Bull 1973; 20: 1–4.
23. Hein HO, Suadicani P, Gyntelberg F. Alcohol consumption, serum low density lipoprotein cholesterol, and risk of ischaemic heart disease. BMJ 1996; 312:736–741.
24. Masarei JR, Puddey IB, Rouse IL, et al. Effects of alcohol consumption on serum lipoprotein-lipid and apolipoprotein concentrations. Results from an intervention study in healthy subjects. Atherosclerosis 1986; 60: 79–87.
25. Huttunen JK, Länsimies E, Voutilainen E, et al. Effect of moderate physical exercise on serum lipoproteins. Circulation 1979; 60: 1220–1229.
26. NIH Consensus Development Panel on Triglyceride, High Density Lipoprotein, and Coronary Heart Disease. JAMA 1993; 269: 505–510.
27. Garber AM, Avins AL. Triglyceride concentration and coronary heart disease: not yet proved of value as a screening test. Br Med J 1994; 309: 2–3.
28. Pocock SJ, Shaper AG, Phillips AN. Concentrations of high density lipoprotein cholesterol, triglycerides, and total cholesterol in ischaemic heart disease. Br Med J 1989; 298: 998–1002.
29. Bainton D, Miller NE, Bolton CH, et al. Plasma triglyceride and high density lipoprotein cholesterol as predictors of ischaemic heart disease in British men: The Caerphilly and Speedwell Collaborative Heart Disease Studies. Br Heart J 1992; 68: 60–66.
30. Schonfeld G. Inherited disorders of lipid transport. Endocrinol Metab Clin North Am 1990; 19: 229–257.
31. Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992; 85: 37–45.
32. Assman G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidense of atherosclerotic coronary artery disease (the PRO-CAM experience). Am J Cardiol 1992; 70: 733–737.
33. Castelli WP. Epidemiology of triglycerides: a view from Framingham. Am J Cardiol 1992; 70:3H-9H.
34. Steinberg D, Witztum JL. Lipoproteins and atherogenesis. Current concepts. JAMA 1990; 264: 3047–3052.
35. Nordestgaard BG, Tybjaerg-Hansen A. IDL, VLDL, chylomicrons and atheroscerosis. Eur J Epidemiol 1992; 8: 92–98.
36. Jeppesen J, Schaaf P, Jones C, et al. Effects of low-fat, high-carbohydrate diets on risk factors for ischemic heart disease in postmenopausal women. Am J Clin Nutr 1997; 65: 1027–1033.
37. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidmia. N Engl J Med 1987; 317: 1237–1245.
38. Robins SJ, Collins D, Wittes JT, et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized trial. JAMA 2001; 285: 1585–1591.
39. Ruotolo G, Ericsson CG, Tettamanti C, et al. Treatment effects on serum lipoprotein lipids, apolipoproteins and low density lipoprotein particle size and relationships of lipoprotein variables to progression of coronary artery disease in the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). J Am Coll Cardiol 1998; 32: 1648–1656.
40. Jeppesen J, Hein HO, Suadicani P, et al. Triglyceride concentration and ischemic heart diesase: An eight-year follow-up in the Copenhagen Male Study. Circulation 1998; 97: 1029–1036.
41. Lithell HO, Pollare T, Berne C. Insulin sensitivity in newly detected hypertensive patients: influence of captopril and other antihypertensive agents on insulin sensitivity and related biological parameters. J Cardiovasc Pharmacol 1990; 15(Suppl 5):S46–S52.
42. Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein (a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996; 77: 1179–1184.
43. Von Eckardstein A, Schulte H, Assmann G. Increased risk of myocardial infarction in men with both hypertriglyceridemia and elevated HDL cholesterol. Circulation 1999; 99: 1922–1926.
44. Ridker, PM, Genest J, Libby P. Risk factors for atherosclerotic disease. In: Braunwald E, Zipes DP, Libby P, eds. Heart disease: a textbook of cardiovascular medicine, 6th ed. Philadelphia: Saunders, 2001: 1010–1039.
45. Ross R. The pathogenesis of atherosclerosis. In: Braunwald E, ed. Heart disease: a textbook of cardiovascular medicine, 5th ed. Philadelphia: Saunders, 1997:1126–1161.
46. Hodis HN, Mack WJ, Azen SP, et al. Triglyceride-and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994; 90: 42–49.
47. Mack WJ, Krauss RM, Hodis HN. Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression. Arterioscler Thromb Vasc Biol 1996; 16: 697–704.
48. Lahdenpera S, Tilly-Kiesi M, Vuorinen-Markkola H, et al. Effects of gemfibrozil on low-density lipoprotein particle size, density distribution, and composition in patients with type II diabetes. Diabetes Care 1993; 16: 584–592.
49. McNamara JR, Jenner JL, Li Z, et al. Change in LDL particle size is associated with change in plasma triglyceride concentration. Arterioscler Thromb 1992; 12:1284–1290.
50. Austin MA, Breslow JL, Hennekens CH, et al. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988; 260: 1917–1922.
51. Brewer HB. Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovscular disease. Am J Cardiol 1999; 83: 3F–12F.
52. Lamarche B, Tchernof A, Mauriège P, et al. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998; 279: 1955–1961.
53. St-Pierre AC, Ruel IL, Cantin B, et al. Comparison of various electrophoretic characteristics of LDL particles and their relationship to risk of ischemic heart disease. Circulation 2001; 104: 2295–2299.
54. Hamsten A, Wiman B, de Defaire U, et al. Increased plasma level of a rapid inhibitorof tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557–1563.
55. Metha J, Mehta P, Lawson D, et al. Plasma tissue plasminogen activator inhibitor levelsin coronary heart disease: correlation with age and serum triglyceride concentrations. J Am Coll Cardiol 1987; 9: 263–268.
56. Hamsten A, de Defaire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3–9.
57. Ruige JB, Assendelft WJJ, Dekker JM, et al. Insulin and risk of cardiovascular disease: a meta-analysis. Circulation 1998; 97: 996–1001.
58. Wingard DL, Barrett-Connor EL, Ferrara A. Is insulin really a heart disease risk factor. Diabetes Care 1995; 18: 1299–1304.
59. Stout RW. Insulin and atheroma: 20-yr perspective. Diabetes Care 1990; 13: 631–654.
60. Nordestgaard BG, Agerholm-Larsen B, Stender S. Effects of exogenous hyperinsulinemia on atherogenesis in cholesterol-fed rabbits. Diabetologia 1997; 40: 512–520.
61. Intensive blood-glucose control with sulphony-lureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKDPS) group. Lancet 1998; 352: 837–853.
62. Knuiman JT, West CE, Katan MB, et al. Total cholesterol and high density lipoprotein cholesterol levels in populations differing in fat and carbohydrate intake. Arteriosclerosis 1987; 7: 612–619.
63. Jeppesen J, Hein HO, Suadicani P, et al. Low triglycerides-high high-density lipoprotein cholesterol and risk of ischemic heart disease. Arch Intern Med 2001; 161: 361–366.
64. Jeppesen J, Hein HO, Suadicani P, et al. Relation of high TG-low HDL cholesterol and LDL cholesterol to the incidence of ischemic heart disease. An 8-year follow-up in the Copenhagen Male Study. Arterioscler Thromb Vasc Biol 1997; 17: 1114–1120.
65. Reaven GM. Syndrome X: past, present, and future. In: Draznin B, Rizza R, eds. Clinical research in diabetes and obisity. Totowa, NJ: Humana Press, 1997:357–382.
66. Warrem JH, Martin BC, Krolewski AS, et al. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Inten Med 1990; 113: 909–915.
67. Lillioja S, Mott DM, Spraul M, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 1988–1992.
68. Zavaroni I, Bonini L, Gasparini P, et al. Hyperinsulinemia in a normal population as a predictor of non-insulin-dependent diabetes mellitus, hypertension, and coronary heart disease: The Barilla factory revisited. Metabolism 1999; 48: 989–994.
69. Salonen JT, Lakka TA, Lakka HM, et al. Hyperinsulinemia is associated with the incidence of hypertension and dyslipidemia in middle- aged men. Diabetes 1998; 47: 270–275.
70. Liese AD, Mayer-Davis EJ, Chambless LE, et al. Elevated fasting insulin predicts incident hypertension: the ARIC study. Atherosclerosis Risk in Communities Study Investigators. J Hypertens 1999; 17: 1169–1177
71. Deprés JP, Lamache B, Mauriège P, et al. Hyperinsulinemia as an independent risk factor for ischaemic heart disease. N Engl J Med 1996; 334: 952–957.
72. Lakka HM, Lakka TA, Tuomilehto J, et al. Hyperinsulinemia and the risk of cardiovascular death and acute coronary and cerebrovascular events in men: the Kuopio Ischaemic Heart Disease Risk Factor Study. Arch Intern Med 2000; 160: 1160–1168.
73. Moller LF, Jespersen J. Fasting serum insulin levels and coronary heart disease in a Danish cohort: 17-year follow-up. J Cardiovasc Risk 1995; 2: 235–240.
74. Howard G, O'Leary DH, Zaccaro D, et al. Insulin sensitivity and atheroscerosis. Circulation 1996; 93: 1809–1817.
75. Yip J, Facchini FS, Reaven GM. Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease. J Clin Endocrinol Metab 1998; 83: 2773–2776.
76. Eriksson J, Franssila-Kallunki A, Ekstrand A, et al. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 1989; 321: 337–343.
77. Vaag A, Henriksen JE, Beck-Nielsen H. Decreased insulin activation of glycogen synthase in skeletal muscles in young nonobese caucasian first-degree relatives of patients with non- insulin-dependent diabetes mellitus. J Clin Invest 1992; 89: 782–788.
78. Ferrari P, Weidemann P, Shaw S, et al. Altered insulin sensitivity, hyperinsulinemia, and dyslipidemia in individuals with a hypertensive parent. Am J Med 1991; 91: 589–596.
79. Facchini F, Chen YD, Clinkingbeard C, et al. Insulin resistance, hyperinsulinemia, and dyslipidemia in nonobese individuals with a family history of hypertension. Am J Hypertens 1992; 5: 694–699.
80. Beatty OL, Harper R, Sheridan B, et al. Insulin resistance in offspring of hypertensive parents. BMJ 1993; 307: 92–96.
81. Kareinen A, Viitanen L, Halonen P, et al. Cardiovascular risk factors associated with insulin resistance cluster in families with early-onset coronary heart disease. Arterioscler Thromb Vasc Biol 2001; 21: 1346–1352.
82. Reaven GM, Chen YD, Jeppesen J, et al. Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles. J Clin Invest 1993; 92: 141–146.
83. Carantoni M, Abbasi F, Warmerdam F, et al. Relationship between insulin resistance and partially oxidized LDL particles in healthy, nondiabetic volunteers. Arterioscler Thromb Vasc Biol 1998; 18: 762–767.
84. Abbasi F, McLaughlin T, Lamendola C, et al. Comparison of plasminogen activator inhibitor-1 concentration in insulin-resistant versus insulin-sensitive healthy women. Arterioscler Thromb Vasc Biol 1999; 19: 2818–2821.
85. Festa A, D'Agostino R Jr, Mykkanen L, et al. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vasc Biol 1999; 19: 562–568.
86. Wayne HHS, Shieh SM, Fuh MMT, et al. Insulin resistance, glucose intolerance, and hyperinsulinemia: hypertriglyceridemia versus hypercholesterolemia. Arterioscler Thromb 1993; 13: 367–370.
87. Karhapää P, Voutilainen E, Kovanen PT, et al. Insulin resistance in familial and nonfamilial hypercholesterolemia. Arterioscler Thromb 1993; 13: 41–47.
88. Lamarche B, Tchernof A, Moorjani S, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Circulation 1997; 95: 69–75.
89. Festa A, D'Agostino R Jr, Mykkanen L, et al. Low-density lipoprotein particle size is inversely related to plasminogen activator inhibitor-1 levels. The Insulin Resistance Atherosclerosis Study. Arterioscler Thromb Vasc Biol 1999; 19: 605–610.
90. Jeppesen J, Facchini FS, Reaven GM. Individuals with high total cholesterol/HDL cholesterol ratios are insulin resistant. J Intern Med 1998; 243: 293–298.
91. Kinosian B, Glick H, Garland G. Cholesterol and coronary heart disease: Predicting risks by levels and ratios. Ann Intern Med 1994; 121: 641–647.
92. Reaven GM, Brand RJ, Chen YD, et al. Insulin resistance and insulin secretion are determinants of oral glucose tolerance in normal individuals. Diabetes 1993; 42: 1324–1332.
93. Nordestgaard BG, Abildgaard S, Wittrup HH, et al. Heterozygous lipoprotein lipase deficiency: frequency in the general population, effect on plasma lipid levels, and risk of ischemic heart disease. Circulation 1997; 96: 1737–1744.
94. Tobey TA, Greenfield M, Kraemer F, et al. Relationship between insulin resistance, insulin secretion, very low density lipoprotein kinetics and plasma triglyceride levels in normo-triglyceridemic man. Metabolism 1981; 30: 165–171.
95. Miesenböck G, Patsch JR. Relationship of triglyceride and high density lipoprotein metabolism. Atheroscler Rev 1990; 21: 119–127.
96. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. High triglycerides-low/HDL cholesterol, ischemic ECG changes, and risk of ischemic heart disease. Am Heart J 2003; 145: 103–108.
97. Knutsen R, Knutsen SF, Curb JD, et al. The predictvie value of resting electrocardiograms for 12-year incidence of coronary heart disease in the Honolulu Heart Program. J Clin Epidemiol 1988; 41:293–302.
98. Sigurdsson E, Sigfusson N, Sigvaldason H, et al. Silent ST-T changes in an epidemiologic cohort study—a marker of hypertension or coronary heart disease, or both: the Reykjavik Study. J Am Coll Cardiol 1996; 27: 1140–1147.
99. De Bacquer D, De Backer G, Kornitzer M, et al. Prognostic value of ECG findings for total, cardiovascular disease, and coronary heart disease death in men and women. Heart 1998; 80: 570–577.
100. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities—the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996; 334: 374–381.
101. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1: prolonged differences in blood presure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765–774.
102. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2: short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827–838.
103. Reaven GM. Are insulin resistance and/or compensatory hyperinsulinemia involved in their etiology and clinical course of patients with hypertension. Int J Obesity 1995; 19(Suppl 1):2–5.
104. Jeppesen J, Hein HO, Suadicani P, et al. High triglycerides and low HDL cholesterol and blood pressure and risk of ischemic heart disease. Hypertension 2000; 36: 226–232.
105. Kaplan NM. Treatment of hypertension: rationale, guidelines, and goals. In: Kaplan NM, ed. Clinical hypertension, 7th ed. Baltimore: Williams & Wilkins, 1998:133–158.
106. Facchini FS, Hua N, Abbasi F, et al. Insulin resistance as a predictor of age-related diseases. J Clin Endocrinol Metab 2001; 86: 3574–3578.
107. Båvenholm P, Proudler A, Tornwall P, et al. Insulin, intact and split proinsulin, and coronary artery disease in young men. Circulation 1995; 92: 1422–1429.
108. Wolf RN, Grundy SM. Influence of weight reduction on plasma lipoproteins in obese patients. Arteriosclerosis 1983; 3: 160–169.
109. Couillard C, Despres JD, Lamarceh B, et al. Effects of endurance exercise training on plasma HDL cholesterol levels depend on levels of triglycerides: evidence from men of the health, risk factors, exercise training and genetics (HERITAGE) family study. Arterioscler Thromb Vasc Biol 2001; 21: 1226–1232.
110. Su HY, Sheu WH, Chin HM, et al. Effect of weight loss on blood pressure and insulin resistance in normotensive and hypertensive obese individuals. Am J Hypertens 1995; 8: 1067–1071.
111. Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343–1350.
112. Dela F. On the influence of physical training on glucose homeostasis. Acta Physiol Scand Suppl 1996; 635:1–41.
113. Mensink RP, Katan MB. Effect of dietary fatty acids on serum lipids and lipoproteins. Arterioscler Thromb 1992; 12: 911–919.
114. West of Scotland Coronary Prevention Group. West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet 1996; 348: 1339–1342.
115. Anderssn OK, Almgren T, Persson B, et al. Survival in treated hypertension: follow-up study after two decades. BMJ 1998; 317: 167–171.